{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05561387","nct_id":"NCT05561387","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05561387. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"INDUCTION CYCLES 1-9: Patients receive bortezomib SC on days 1, 8, 15, and 22 of each cycle, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm I (VRd-Lite)","type":"ACTIVE_COMPARATOR"},{"description":"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm II (DRd-R)","type":"EXPERIMENTAL"},{"description":"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE CYCLES 10+: Patients receive daratumumab and hyaluronidase-fihj SC on day 1 of each cycle and lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm III (DRd-DR):","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2031-05-30","type":"ESTIMATED"},"conditions":["Plasma Cell Myeloma"],"enrollment":{"count":510,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bortezomib","type":"DRUG"},{"name":"Daratumumab and Hyaluronidase-fihj","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"}],"last_update":"2026-06-10","lead_sponsor":"SWOG Cancer Research Network","official_title":"A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of \"Intermediate Fit\" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-05-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) of Arm 1 versus (vs.) Arm 2","timeFrame":"From date of randomization to date of first documentation of progression or symptomatic deterioration, or death due to any cause, or assessed up to 10 years"},{"measure":"Overall survival (OS) of Arm 1 vs. Arm 3","timeFrame":"From date of randomization to date of death due to any cause, or assessed up to 10 years"}],"references":[],"start_date":{"date":"2023-10-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","url":"https://clinicaltrials.gov/study/NCT05561387"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05561387"}